BIOMERICA INC
No enriched coverage for $BMRA in the last 7 days.
Biomerica Inc. raised $2.23M in private placement funding. Q4 sales rose 17% to $875K, while net loss narrowed 27% to $1.5M. The company secured a $1.75M contract for diagnostic assay development and expanded into the Canadian market. Shares trade around $2.09 (Nasdaq: BMRA).
BIOMERICA INC (BMRA) reported FY 2026 revenue of $4.45M, down 16% YoY, and a net loss of $3.78M, improved from $4.97M in FY 2025. EPS was $(1.30), up from $(2.16). Revenue decline was due to lower clinical lab and OTC volumes. The company secured a CPT code and Medicare rate for inFoods® IBS and entered agreements targeting $1.75M in fees.
Carets Corp is exploring a potential sale, including its technology and patents. Algorhythm Holdings (RIME) and Biomerica (BMRA) are evaluating strategic alternatives. nVent Electric (NVT) acquired Maverick Power for $1.75B, with up to $550M more in performance-based payments. Descartes (DSGX) bought Tai for $100M, and Navitas (NVTS) acquired Claros for up to $232.8M. Booz Allen (BAH) completed a $720M acquisition, and Elastic (ESTC) acquired Deductive AI. BioXcel (BTAI) filed for Chapter 11 ban
Recent BMRA coverage spans insider activity, earnings and mergers & acquisitions.
In the last 30 days, BMRA insiders filed 4 SEC Form 4 transactions — 4 purchases ($108K) and no sales. The most active reporter was Irani Zackary S., Chief Executive Officer, with 1 filing.
The capital raise and improved quarterly results may support short‑term price upside.
Earnings beat loss expectations, modest revenue decline; may support short‑term price stability for a micro‑cap.
Advisory engagement may lead to a deal that moves the stock.
Small insider purchase by a director may signal confidence but the amount is modest.
Small insider purchase by a director; unlikely to move the stock materially.
AlphAI scores every news story that mentions BMRA with an AI model for sentiment and relevance, and aggregates insider trades from BIOMERICA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biomerica Inc. raised $2.23M in private placement funding. Q4 sales rose 17% to $875K, while net loss narrowed 27% to $1.5M. The company secured a $1.75M contract for diagnostic assay development and expanded into the Canadian market. Shares trade around $2.09 (Nasdaq: BMRA).
2 min readBIOMERICA INC (BMRA) reported FY 2026 revenue of $4.45M, down 16% YoY, and a net loss of $3.78M, improved from $4.97M in FY 2025. EPS was $(1.30), up from $(2.16). Revenue decline was due to lower clinical lab and OTC volumes. The company secured a CPT code and Medicare rate for inFoods® IBS and entered agreements targeting $1.75M in fees.
1 min readCarets Corp is exploring a potential sale, including its technology and patents. Algorhythm Holdings (RIME) and Biomerica (BMRA) are evaluating strategic alternatives. nVent Electric (NVT) acquired Maverick Power for $1.75B, with up to $550M more in performance-based payments. Descartes (DSGX) bought Tai for $100M, and Navitas (NVTS) acquired Claros for up to $232.8M. Booz Allen (BAH) completed a $720M acquisition, and Elastic (ESTC) acquired Deductive AI. BioXcel (BTAI) filed for Chapter 11 ban
3 min readGary M. Huff purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-20.
1 min readMOATAZEDI DAVID purchased 10,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readChin Eric purchased 6,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readBARBIERI ALLEN (Executive Vice Chairman) purchased 20,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readIrani Zackary S. (Chief Executive Officer) purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readBIOMERICA INC (BMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement On August 20, 2026, Biomerica, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and individual investors identif
2 min readBiomerica Inc. said it was selected for a $1.75 million master services agreement with an undisclosed life sciences company to develop in vitro diagnostic assays. The three-year work will be performed at Biomerica’s Irvine facility, according to the company. Biomerica said the initial fees provide near-term revenue visibility. Shares fell 2.2% to $2.40.
3 min read
